Completed: Potential New Treatment for Brain DiseasesNRR Series Webinar: Title: Potential New Treatment for Brain Diseases Date and Time: THURSDAY, April 27th 20:30-21:40 (Beijing, China) | 7:30 am - 8:30 am (Central Daylight Time) | 14:30-15:40 (Central European Time)
PROGRAM
Speaker 1:
Associate Professor Department of Health Science and Technology, Aalborg University, Denmark Speech Title: Metabolism as the driving force in brain diseases: CPT1 as a common target for treatment
About the speaker: The aim of Dr. Nieland’s research is to study brain diseases and identify how brain diseases develop and progress. Based on this research his group want to develop treatment strategies to help patients suffering from diseases like Multiple Sclerosis, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease Huntington's disease and others. Give these patients a possibility to treat themselves through diet, food additives, vitamins, and also to develop new classes of medicine. Their overall aim is to discover new therapeutic strategies, develop better drugs, optimize their effectiveness, reduce unwanted side effects, and understand the response with a unique patient-centred approach. They use advanced research methods from bench to bedside to investigate the complex mechanisms underpinning diseases and optimize therapeutic approaches.
Speaker 2 (Session Chair):
Professor Department of Neuroscience, Institute for Translational Neuroscience, University of Minnesota, USA Speech title: The PERK-NF-κB pathway protects oligodendrocytes against inflammation in animal models of multiple sclerosis About the speaker: The major focus of the laboratory is to understand the mechanisms of demyelination, remyelination and neurodegeneration in multiple sclerosis and to develop therapeutic strategies that preserve myelin and axons in this disease. They generate sophisticated genetic mouse models that allow for inactivation or activation of genes of interest specifically in oligodendrocytes or neurons, and then exploit these mouse models to determine the roles of these genes in oligodendrocytes or neurons in mouse models of multiple sclerosis and their underlying mechanisms. Their work utilizes sophisticated mouse models to dissect the precise role of individual branch of the unfolded protein response in myelin disorders, neurodegenerative diseases, and brain tumors. These studies could provide mechanistic insight necessary for designing novel therapeutic strategies for patients with these diseases.
PANELIST 1: Yinzhong Ma AssociateProfessor Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, China About the Panelist: My major research interests focus on therapeutic targets and new drug development for cerebrovascular lesions. Many pathological processes of the nervous system involve changes in the structure or function of the cerebrovascular system. Due to the extreme sensitivity of brain tissue to the microenvironment and its high energy demand, cerebrovascular lesions are not only a direct cause of many neurological diseases, but also indirectly hinder the implementation of other treatments. Therefore, exploration of the molecular mechanisms and appropriate therapeutic targets of cerebrovascular lesions can not only provide direct protection for brain tissue, prevent and treat cerebrovascular damage, but also lay a foundation for subsequent treatments such as thrombolysis and nerve regeneration.
PANELIST 2: Zhaolan Hu AssistantProfessor Department of Anesthesiology, The Second Xiangya Hospital, Central South University, China About the Panelist: Her research interests focus on: Immunology research of autoimmune diseases (multiple sclerosis, Rheumatoid Arthritis)and cardiovascular disease(Coronary Artery Disease). The relevant studies of monocytes/macrophages, lymphocytes and neutrophils in immune-mediated inflammatory disease. To study the mechanisms of proBDNF-p75NTR signal regulating lymphocytes cells in autoimmune diseases, to provide a solid foundation for further development of humanized proBDNF monoclonal antibodies in the treatment of autoimmune diseases.
|
Wensheng Lin